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(Fosrenol) and calcium carbonate on renal bone disease in
Conclusion. LC is a poorly absorbed, well-tolerated, and dialysis patients. efficient phosphate binder. LC-treated dialysis patients show Background. Lanthanum carbonate (LC) (Fosrenol) is a almost no evolution toward low bone turnover over one year novel new treatment for hyperphosphatemia. In this phase III, (unlike CC-treated patients), nor do they experience any alumiopen-label study, we compared the effects of LC and calcium num-like effects on bone. carbonate (CC) on the evolution of renal osteodystrophy (ROD) in dialysis patients.
Methods. Ninety-eight patients were randomized to LC (N ϭ 49) or CC (N ϭ 49). Bone biopsies were taken at baseline Hyperphosphatemia continues to be a challenge for and after one year of treatment. Acceptable paired biopsies the clinical nephrologist, as it may lead to extraosseous were available for static and dynamic histomorphometry studcalcification of both vascular and nonvascular tissues, ies in 33 LC and 30 CC patients. Blood samples were taken at regular intervals for biochemical analysis and adverse events secondary hyperparathyroidism, and osteitis fibrosa, parwere monitored. ticular types of renal osteodystrophy (ROD) responsiResults. LC was well tolerated and serum phosphate levels ble for significant morbidity [1, 2]. To prevent hyperwere well controlled in both treatment groups. The incidence phosphatemia, most patients with end-stage renal failure of hypercalcemia was lower in the LC group (6% vs. 49% for require an exogenous phosphate binder. CC). At baseline, subtypes of ROD were similarly distributed in both groups, with mixed ROD being most common. At oneAluminium-containing phosphate binders have been year follow-up in the LC group, 5 of 7 patients with baseline widely used in the past. The systemic absorption of alulow bone turnover (either adynamic bone or osteomalacia), minium hydroxide over time, however, can lead to the and 4 of 5 patients with baseline hyperparathyroidism, had development of the so-called aluminium-related bone evolved toward a normalization of their bone turnover. Only diseases (either osteomalacia or adynamic bone), deone lanthanum-treated patient evolved toward adynamic bone compared with 6 patients in the CC group. In the LC group, mentia, and more subtle disorders at the level of the the number of patients having either adynamic bone, osteomaparathyroid gland, hematopoiesis, and myopathy [3, 4] . lacia, or hyperpara decreased overall from 12 (36%) at baseline The use of calcium salts for phosphate binding is complicated by the development of hypercalcemia and an increased risk of metastatic calcifications in a substantial fraction of patients, particularly those taking vitamin D analogs and those with adynamic bone disease [5] [6] [7] . 
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Alternative phosphate binders have been developed modialysis or CAPD) within the 12 weeks prior to study in recent years with the aim of avoiding side effects entry, or had been diagnosed with chronic renal failure during phosphate control. Polyallylamine-hydrochloride and were scheduled to begin dialysis prior to randomiza-(sevelamer, RenaGel) is a nonabsorbed cationic polytion. No preset limit was applied to serum PTH on entry mer that binds phosphate anions through ion exchange to the study and there was no restriction of concomitant and hydrogen binding. This class of compounds was origvitamin D therapy. Patients with significant hypocalinally developed to lower plasma lipids; this effect is still cemia or concurrent illness were excluded. seen with sevelamer [8] . Compared to calcium-based A total of 98 patients ('intent to treat' patients) were phosphate binders, evidence has shown that with severandomized to the study medication and received at least lamer, fewer coronary and aortic calcifications are seen one dose of lanthanum carbonate (N ϭ 49) or calcium [9] . However, the efficacy of this polymer in lowering carbonate (N ϭ 49). In this group all aspects of efficacy, phosphate levels is still a matter of debate, as the target safety, and tolerability were monitored. Safety was asserum phosphate level of 5.5 mg/dL cannot be reached in sessed at each study visit by recording adverse events the majority of patients, especially when the compound is and vital signs. Full blood biochemical and hematologic used as monotherapy [10] . Moreover, as a lipid-binding parameters were monitored and the plasma levels of compound, sevelamer has the ability to sequester fatlanthanum were measured at visits throughout the study. soluble vitamins and nutrient compounds [11] . Although Patients were recruited from 18 centers in 12 countries. no problems in this respect have emerged so far, more
The mean Ϯ SD age was 55 Ϯ 14.3 years; 59 (60%) information on long-term safety is required.
patients were males. There was no relevant difference Because the solubility product of trivalent iron and between treatment groups with respect to underlying phosphate is extremely low, polynuclear iron preparanephrologic diagnosis: diabetes (26%); glomerulonetions constitute another group of alternative phosphate phritis (9%); other known disease (12%); unknown binders. The use of trivalent iron has recently generated cause (14%); cystic kidney disease (14%); hypertension substantial interest; it is effective and well tolerated, but (14%); and urologic disease (10%). is still in the early stages of clinical development [12] .
A total of 68 patients (N ϭ 34 in each group) com-A third alternative is lanthanum carbonate. Lanthapleted the study (i.e., underwent a bone biopsy at basenum, discovered in 1839 by Mosander, is a rare earth line and follow-up. Patients discontinued the study beelement (molecular weight: 139 kD). As this trivalent cause of the investigator's decision (N ϭ 1); protocol hard acid cation has a high affinity for phosphate (phosviolation (N ϭ 1); kidney transplantation (N ϭ 10); death phate binding capacity in vitro Ͼ97%), is minimally absorbed gastrointestinally, is not excreted by the kidneys, (N ϭ 11); serious adverse events (N ϭ 2); and others and is well tolerated, the investigation of lanthanum as (N ϭ 5). Of the patients randomized, 63 pairs of bone a phosphate binder is warranted [13] . The excretion of biopsies were suitable for histomorphometric measureabsorbed lanthanum by the biliary system contrasts with ments, 33 of which belonged to the lanthanum group aluminium, which is excreted almost entirely (Ͼ95%) and 30 to the calcium group. in the urine and, consequently, is associated with an Written informed consent was obtained from all paincreased risk of toxicity in patients with renal disease tients and the study was conducted in compliance with [14] . Plasma lanthanum concentrations have rarely exthe declaration of Helsinki and approved by Local Ethiceeded one part per billion. There has been no evidence cal Committees at each of the participating centers. of lanthanum toxicity in any of the clinical studies hitherto performed.
Study set up In light of the past tragic experience with aluminium in The study was conducted over a one-year period. Foldialysis patients, information on the effects of lanthanum lowing screening, all phosphate binders were stopped carbonate on bone is necessary. The present bone and double tetracycline labeling administered, with an biopsy-based study aimed to: investigate the effect of interval of 8 to 12 days. A baseline bone biopsy was phosphate management by the administration of lanthataken 2 to 6 days following the second label. Patients num carbonate compared with calcium carbonate on rewere then randomized in a 1:1 ratio to receive lanthanum nal bone disease; check the lanthanum accumulation in or calcium carbonate. All patients were titrated to a bone; and evaluate long-term safety and tolerability of lanthanum dose (up to 3750 mg/day) or calcium (up to lanthanum in dialysis patients after one year of treat-9000 mg/day) that achieved optimal reduction of serum ment.
phosphate levels, and were maintained at this dose, or titrated further when necessary. The second biopsy was METHODS obtained following double tetracycline labeling and one Patients year of treatment, or at time of discontinuation if Ͼ6 months treatment received. A follow-up period was inKey inclusion criteria were male or female patients aged Ͼ18 years who had started dialysis treatment (hecluded, during which patients were examined and all
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adverse events reviewed 28 days after discontinuation There was, however, a higher incidence of hypercalcemia of the study medication (or early withdrawal from the (serum calcium above upper limit of normal) (i.e., Ͼ2.65 study).
mmol/L or Ͼ10.6 mg/dL) in the patients treated with calcium carbonate (49%) compared to those receiving Laboratory methods lanthanum carbonate during the study period (6%). Blood and bone biochemistry. Blood samples were There were no significant differences in hematologic taken at study visits throughout the study period for the or biochemical safety parameters over time. A more determination of a series of routine biochemistry and detailed description of clinical safety results will be prehematology screening tests. In addition, a panel of serum sented elsewhere. parameters relevant to bone [i.e., phosphorous, calcium, There were no significant differences in the concentrabone specific and total alkaline phosphatase, iPTH, 25-tion of the various biochemical bone-related parameters (OH)-, vitamin D, and 1,25-(OH) 2 vitamin D] were meabetween the two groups; these parameters also did not sured using the appropriate kits and methodologies.
significantly change during the study period (Fig. 1) . Lanthanum was measured in plasma and bone by Both treatment groups showed well controlled phosphomeans of inductively-coupled plasma mass spectrometry rus levels throughout the trial, using doses up to 3750 (ICP-MS) using methodologies developed and optimized mg/day for lanthanum (median dose 1250 mg/day), and at the Centre for Analytical Sciences (CAS) at the Uni-9000 mg/day (median dose 2000 mg/day) for calcium versity of Sheffield, United Kingdom.
carbonate. With respect to vitamin D usage, no differBone histomorphometry. In each patient, a single ences were noticed between treatment groups (lanthatransiliac bone biopsy (Ϯ 1 cm length; 5 or 7 mm diamenum: 63% vs. calcium: 53%). ter) was taken after double tetracycline labeling. The
Patients of the lanthanum group had plasma lanthabiopsy was divided into two parts. One part (mainly num levels that were slightly increased for all doses adcortical bone) was used to measure the bulk lanthanum ministered, compared with baseline levels of patients content. The remaining part was fixed in absolute ethanol receiving 1500 to 2250 mg lanthanum per day, with mean and then embedded in a methylmethacrylate-based resin plasma lanthanum levels ranging from 0.51 to 1.08 g/L. for histology and histomorphometric analysis. UndeLanthanum levels did not depend on the dose adminiscalcified 7-m thick sections were stained with Toluidine tered and reached a plateau after 12 weeks of treatment. blue [15] . Seven-m sections were mounted unstained
The patients treated with lanthanum carbonate for up in immersion oil for visualization of tetracycline labels.
to one year had a median bone concentration of 1.8 g/g, Criteria for classification of the various types of ROD the highest value in any patient being 5.5 g/g. In the calwere: cium carbonate group, bone lanthanum levels at the end of the study also showed a slight increase, with the highAdynamic bone disease: Bone formation rate (BFR) est value in any patient being 1.0 g/g. Ͻ5% of age-and sex-corrected mean and osteoclast
The histomorphometric data are shown in Figure 2 . surface (OcS) Ͻ20% of age-and sex-corrected mean.
Five out of 7 patients (71%) of the lanthanum group Hyperparathyroidism: BFR Ͼ2x age-and sex-corrected with either adynamic bone or osteomalacia at baseline mean and OcS Ͼ100x age-and sex-corrected mean. (Fig. 2, upper panels) , and 4 out of 5 patients (80%) with Normal: BFR and OcS within 2SD of the age-and sexbaseline hyperparathyroidism (Fig. 2 , lower panels) corrected mean.
evolved toward a normalization of their bone turnover Osteomalacia: Mineralization lag time (MLT) Ͼ100 days as compared to only 3 out of 7 (42%) and 3 out of 6 and osteoid volume Ͼ5x age-and sex-corrected mean.
(50%) of the calcium group. Mixed ROD: All bone biopsies that do not fulfill the Twenty-six (26) patients (79%) of the lanthanum criteria listed above.
group and 23 (77%) of the calcium group had a normal or increased bone turnover (hyperpara, mixed, normal) RESULTS at baseline. Both groups showed markedly different responses. While 6 out of 23 patients (26%) of the calcium Lanthanum carbonate taken with meals was well tolergroup developed adynamic bone disease, this was seen ated throughout the study period. The type and incidence in only 1 out of 26 patients (4%) of the lanthanum group of adverse events were well balanced between the two (Fig. 2, upper panels) . This particular lanthanum-treated treatment groups, with 96% of patients in both groups patient had been taking oral calcitriol throughout the reporting at least one treatment-emergent adverse effect. study at varying doses (0.5 to 1.5 g TDS), despite having Gastrointestinal effects were the most common events a PTH (baseline, 4.56 pmol/L to follow-up, 5.53 pmol/L) and were typically mild (lanthanum: 53% vs. calcium: below the optimum level for an end-stage renal failure 49%). Withdrawal rates due to adverse events were comparable between lanthanum (24%) and calcium (22%).
patient, and having a good control of serum phosphate
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The distribution of the various types of ROD assessed at baseline using the proposed criteria for classification was similar in both treatment groups (Fig. 2, lower  panels) .
Overall, in the lanthanum group the total number of patients having either adynamic bone, osteomalacia, or hyperpara decreased from 12 (36%) at baseline, to 6 (18%) at one-year follow-up, while in the calcium group, the number of patients with these types of ROD increased from 13 (43%) to 16 (53%) (Fig. 2, lower panels) .
DISCUSSION
Treatment of uremic hyperphosphatemia remains a major challenge to the nephrologist because phosphate retention is associated with a variety of clinical problems, including secondary hyperparathyroidism and soft tissue mineralization.
Until now, aluminium-containing and calcium-based phosphate binders have been most frequently used in the treatment of hyperphosphatemia. Although highly efficacious, the chronic therapeutic use of these compounds goes along with serious side effects [3] [4] [5] 16] . Lanthanum carbonate has recently been proposed as a nontoxic and efficacious alternative.
In this phase III, open-label study, we compared the effects of a one-year treatment with either lanthanum carbonate or calcium carbonate on the evolution of renal bone disease in dialysis patients.
The serious adverse events for both treatment groups observed during the study period were balanced and were typical for a population with chronic renal failure receiving hemodialysis or peritoneal dialysis. Thus, data of the present study confirms the safe profile of lanthanum previously observed in phase II studies [17] . The incidence and types of adverse effects were similar in the two treatment groups. An exception to this was hypercalcemia, which was appreciably lower in the lanthanum-treated group compared to the calcium carbonate group (6% and 49%, respectively).
Despite the additional calcium intake in the calcium carbonate group, mean serum calcium levels did not differ significantly between the groups, which must be ascribed to careful monitoring of calcemia throughout the study and immediate adjustment of the dialysate the number of hypercalcemic episodes was substantially greater in the calcium carbonate group. This reduced propensity for hypercalcemic episodes on lanthanum car-(mean, 1.53 mmol/L) and serum calcium (mean, 2.38 bonate must be considered a major benefit. mmol/L) throughout the study period.
The serum phosphate levels were well controlled in Five patients (1 with osteomalacia and 4 with mixed both treatment groups throughout the study. There was bone disease at baseline) of the calcium group (17%) little change in iPTH or bone alkaline phosphatase condeveloped hyperpara compared to only 2 patients (mixed centration in either treatment group during the study bone disease at baseline) of the lanthanum group (7.5%) (Fig. 2, lower panels) . period. Weighing any toxic effects of lanthanum against those in bone and plasma after a one-year treatment, being 10-to 50-fold lower than those expected for aluminium experienced in the past with aluminium, the highly limited gastrointestinal absorption of lanthanum (0.00003% [4] . Data furthermore has indicated that plasma lanthanum reached steady state early (i.e., after 12 weeks) in for lanthanum vs. 0.02% for aluminum), and the nonrenal routes of excretion for the absorbed fraction of the the study.
To the best of our knowledge, this is the first bone dose of lanthanum should be considered [18] . This is reflected by the very low concentrations of lanthanum found biopsy-based multicenter study to investigate and com-
